AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings

AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge with several candidates having blockbuster potential.

AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy?

Diageo

Unilever

Keir Stamer's style is the polar opposite of Donald Trump. Many wondered if he was too boring to be U.K. Prime Minister.

These Stocks Offer Gains Without the U.S. Political Drama

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term

In the closing of the recent trading day, Astrazeneca (AZN) stood at $79.76, denoting a +1.49% change from the preceding trading day.

Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Astrazeneca (AZN) is a Strong Growth Stock

LYON, France and CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced that its previously announced acquisition by the global pharmaceutical company, AstraZeneca, has closed.

AstraZeneca Closes Acquisition of Amolyt Pharma

British pharmaceuticals megacap AstraZeneca PLC (LSE:AZN) shares surged nearly a percentage point higher on Friday, reflecting what broker Shroe Capital Markets sees as a “catalyst-rich period ahead”. “AstraZeneca outlined its ‘bold ambition' to deliver $80bn revenue by 2030 during its recent Investor Day, something we believe looks readily deliverable given the depth, breadth and momentum of the R&D pipeline, particularly in oncology,” said Shore Cap.

AstraZeneca has a 'catalyst-rich' period ahead

Abbott Labs

Intuitive Surgical

Merck

PACS Group, Inc.

Pfizer

Tenet Healthcare

In my view, it's important for every individual to invest in equities. By just holding cash in a back account, there is bound to be loss of purchasing power when adjusted for inflation.

7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns

The European Commission approves AstraZeneca's (AZN) Tagrisso in combination with chemotherapy for first-line treatment of advanced EGFR-mutated NSCLC based on data from the phase III FLAURA2 study.

AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC

BAE Systems PLC

British American Tobacco

National Grid

Polar Power

RELX

Smith & Nephew

Unfortunately, UK investors have had to suffer weak or negative capital gains in recent years to get those high yields. The good news is that the UK remains an attractive market for dividend investors. Don't forget that companies usually retain some of their earnings to fund expansion and growth, so dividends have (on average) grown ahead of inflation over the medium and long term,.

U.K. Top 40 Quality Dividend Stocks: Summer 2024

Shares of Aptamer Group PLC (AIM:APTA) were up 12% after announcing a new collaboration with AstraZeneca PLC (LSE:AZN) to explore the use of Optimer technology for targeted delivery of siRNA, a type of genetic material used in therapies. Optimers are synthetic molecules designed to bind specifically to target cells, enhancing the delivery and effectiveness of treatments.

Aptamer Group up 12% on AstraZeneca collaboration

The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study.

AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use

Alphabet

Walmart

One of the greatest forces in wealth-building is the power of compounding. That is why every portfolio needs some set-it-and-forget-it stocks.

3 Set-It-and-Forget-It Stocks for Lasting Financial Security

AstraZeneca said on Monday the EU drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, Sipavibart, under an accelerated assessment.

AstraZeneca's COVID prevention drug application gets EU fast-track assessment

Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

Sanofi

Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infection RSV.

German vaccine panel endorses Astra-Sanofi's RSV shot for infants

Boston Scientific

Corcept Therapeutics

Crinetics Pharmaceuticals Inc

Cytokinetics

Jazz Pharmaceuticals

Zoetis

While innovations such as artificial intelligence have become all the rage, there's another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven't considered the sector, it's really time to focus on biotech stocks.

7 Biotech Stocks to Boost Your Portfolio to Peak Health

Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.

AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer

KIRKLAND, Wash.--(BUSINESS WIRE)--Tanium today shared the success story of customer AstraZeneca in securing over 125,000 endpoints across 125 countries using the Tanium XEM platform.

Tanium Plays Critical Role in Supporting AstraZeneca's Mission to Deliver Life-Changing Medicines

China has approved the use of AstraZeneca's blockbuster cancer drug Tagrisso in combination with chemotherapy as a first line of treatment for adults with a type of advanced lung cancer, the company said on Wednesday.

China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment

AstraZeneca is becoming a leader in the cancer therapeutics market, which is reflected in the growth of its share price. On June 25, 2024, Tagrisso, in combination with chemotherapy, was approved in Japan as the first-line treatment for people with NSCLC whose tumors have certain mutations. Tagrisso sales were about $1.6 billion in the first three months of 2024, up 12% year-over-year.

AstraZeneca's Oncology Success: Fueling Future Growth

AstraZeneca PLC (LSE:AZN) has put out mixed data for the Phase III trials of its immuno-oncology (IO) drug Imfinzi, notes broker ShoreCap. There was a positive result from the Phase III NIAGARA trial looking at its use perioperatively (either side of surgery) for the treatment of bladder cancer (MIBC).

AstraZeneca still a buy for one broker despite mixed Imfinzi data

AstraZeneca PLC (LSE:AZN) shared some disappointing news on an advanced lung cancer trial of its Imfinzi immunotherapy. Phase III trials showed the drug did not achieve statistical significance for its primary endpoint of disease-free survival compared to placebo in early-stage non-small cell lung cancer.

AstraZeneca disappointed with failure of immunotherapy in early-stage lung cancer

BenevolentAI (OTC:BAIVF) said that AstraZeneca PLC (LSE:AZN) has identified a target for systemic lupus erythematosus (SLE) using the former's artificial intelligence-driven drug discovery platform - the second asset selected as part of a collocation the pair have.   Benevolent's tie-up with AZ began in 2019, focusing on idiopathic pulmonary fibrosis and chronic kidney disease.

BenevolentAI says second target identified by AstraZeneca collaboration

News for AstraZeneca Stock (AZN)